Plasma Fractionation Market Growth & Trends
The global plasma fractionation market is expected to reach USD 58.24 billion by 2030, expanding at a CAGR of 8.3%, according to a new report by Grand View Research, Inc. The major factors driving the market growth are the rising prevalence of respiratory illnesses globally, blood-related diseases, and an aging population that is prone to a variety of rare disorders. These are the main drivers of market expansion. In addition, the rise in the prevalence of rare disorders that call for plasma therapy or derivatives also supplemented the market growth.
The global market is also expanding due to the increased use of immunoglobulins as well as alpha-1-antitrypsin in various areas of research around the world. Another important factor for the expansion of the market is the rise in blood collection facilities globally. For instance, as per the WHO, as of May 2022, over 118 million blood donations were collected across the globe, thus increasing the plasma supply gradually. Additionally, supportive government initiatives to raise public awareness about the usage of plasma-derived products also serve as a major driver of the global market’s expansion.
Blood plasma transfusions are one of the cutting-edge treatments for COVID-19 infection. For instance, in August 2020, the US Food and Drug Administration (USFDA) granted the convalescent plasma treatment of COVID-19 an emergency use authorization (EUA). Additionally, in February 2021, it published an amended directive for the plasma EUA for COVID-19. As a result, the usage of plasma fractionation technologies is projected to increase during the COVID-19 pandemic.
The growing demand for personalized medications has increased R&D spending, and technological advancements in plasma components such as immune serum globulin, which have advantages such as higher yield, lower cost, and faster throughput, are driving market growth. On the other hand, immunoglobulins generated from plasma are being employed more frequently for a variety of clinical conditions, including autoimmune and inflammatory illnesses. Therapies including Ceruloplasmin, IgA, and Plasmin have received significant funding from the plasma fractionation sector. Additionally, the industry will receive a boost from booming investments in innovation and technology developments that result in efficient and affordable methods for fractionating proteins. thus, propelling the market’s growth.
For companies operating market-related businesses, the market offers a lot of opportunities. In addition, the global and regional market participants are actively implementing organic and inorganic development strategies as a result of the market’s favorable expansion. As a result, it is anticipated that the market will draw more notable investments during the forecast period. For instance, in January 2022, the eighth plasma collection facility in the Czech Republic was opened by Biotest AG. The national public health authority, SUKL, granted the company an operating license for these centers.
Request a free sample copy or view report summary: Plasma Fractionation Market Report
Plasma Fractionation Market Report Highlights
By product, the immunoglobulins segment held the largest share in 2021. This is anticipated to be driven by rising research activities and the growing demand for immunoglobulin for the treatment of various neurological diseases such as dementia, Alzheimer’s, and others
By application, the neurology segment accounted for the largest share in 2021. This is attributed to the growing demand for efficient neurovascular treatments fueled by the rising prevalence of patients with neurovascular diseases such as cerebral aneurysms, brain stroke, and epilepsy
By the method, the centrifugation segment held a larger share in 2021. The treatment and diagnostic procedures of numerous chronic and infectious diseases become more complex. For these purposes, the use of modern laboratory centrifuges is becoming a crucial method
By end-use, the hospitals & clinics segment held a larger share in 2021. The hospitals & clinics are using plasma-derived products more frequently to treat autoimmune disorders like type 1 diabetes, as well as the improved infrastructure and healthcare facilities, augment the market growth
North America held the larger share in 2021. This is due to the region’s advanced healthcare facilities and favorable governmental policies, which are expected to increase demand for the product
The Asia Pacific is expected to grow at the highest rate in a projected time. Driven by factors such as the rising prevalence of target diseases with an aging population, rising plasma-based therapeutics adoption, and others
List of Key Players of Plasma Fractionation Market
Grifols S.A.
CSL Limited
Takeda Pharmaceutical Company Limited
Octapharma AG
Kedrion S.p.A
LFB S.A.
Biotest AG
Sanquin
Bio Products Laboratory Ltd.
Intas Pharmaceuticals Ltd.
Comments